Literature DB >> 25610745

Cancer chemotherapy agents target intratumoral dendritic cells to potentiate antitumor immunity.

Philipp Müller1, Kea Martin1, Sebastian Theurich2, Michael von Bergwelt-Baildon2, Alfred Zippelius3.   

Abstract

Cytotoxic drugs capable of killing cancer cells in conjunction with targeted conversion of tumor resident, tolerogenic dendritic cells (DCs) into efficient antigen presenting cells (APCs) are highly complementary therapeutic routes to boost antitumor immunity. Our data suggest that the microtubule-depolymerizing compounds Dolastatin 10 and Ansamitocin P3 may serve as prototypes for a class of agents that display this binary mode of action.

Entities:  

Keywords:  DC maturation; T cells; anti-tumor immunity; antibody-drug conjugates; cancer; immune response; microtubule-depolymerizing chemotherapy

Year:  2014        PMID： 25610745      PMCID： PMC4292760          DOI： 10.4161/21624011.2014.954460

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  10 in total

1.  The tumoricidal activity of memory CD8+ T cells is hampered by persistent systemic antigen, but full functional capacity is regained in an antigen-free environment.

Authors:  Annemieke Th den Boer; Geertje J D van Mierlo; Marieke F Fransen; Cornelis J M Melief; Rienk Offringa; René E M Toes
Journal:  J Immunol       Date:  2004-05-15       Impact factor: 5.422

2.  Tumor immunotherapy directed at PD-1.

Authors:  Antoni Ribas
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

3.  Breakthrough of the year 2013. Cancer immunotherapy.

Authors:  Jennifer Couzin-Frankel
Journal:  Science       Date:  2013-12-20       Impact factor: 47.728

4.  Brentuximab vedotin combined with donor lymphocyte infusions for early relapse of Hodgkin lymphoma after allogeneic stem-cell transplantation induces tumor-specific immunity and sustained clinical remission.

Authors:  Sebastian Theurich; Joke Malcher; Kerstin Wennhold; Alexander Shimabukuro-Vornhagen; Jens Chemnitz; Udo Holtick; Anke Krause; Carsten Kobe; Deniz Kahraman; Andreas Engert; Christof Scheid; Geothy Chakupurakal; Michael Hallek; Michael von Bergwelt-Baildon
Journal:  J Clin Oncol       Date:  2012-12-26       Impact factor: 44.544

5.  Improved survival with ipilimumab in patients with metastatic melanoma.

Authors:  F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

6.  The microtubule-depolymerizing agent ansamitocin P3 programs dendritic cells toward enhanced anti-tumor immunity.

Authors:  Kea Martin; Philipp Müller; Jens Schreiner; Spasenija Savic Prince; Didier Lardinois; Viola A Heinzelmann-Schwarz; Daniela S Thommen; Alfred Zippelius
Journal:  Cancer Immunol Immunother       Date:  2014-06-07       Impact factor: 6.968

Review 7.  Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy.

Authors:  Omid Hamid; Richard D Carvajal
Journal:  Expert Opin Biol Ther       Date:  2013-02-19       Impact factor: 4.388

Review 8.  Immunogenic cell death in cancer therapy.

Authors:  Guido Kroemer; Lorenzo Galluzzi; Oliver Kepp; Laurence Zitvogel
Journal:  Annu Rev Immunol       Date:  2012-11-12       Impact factor: 28.527

9.  Microtubule-depolymerizing agents used in antibody-drug conjugates induce antitumor immunity by stimulation of dendritic cells.

Authors:  Philipp Müller; Kea Martin; Sebastian Theurich; Jens Schreiner; Spasenija Savic; Grzegorz Terszowski; Didier Lardinois; Viola A Heinzelmann-Schwarz; Max Schlaak; Hans-Michael Kvasnicka; Giulio Spagnoli; Stephan Dirnhofer; Daniel E Speiser; Michael von Bergwelt-Baildon; Alfred Zippelius
Journal:  Cancer Immunol Res       Date:  2014-04-21       Impact factor: 11.151

10.  Tumor-altered dendritic cell function: implications for anti-tumor immunity.

Authors:  Kristian M Hargadon
Journal:  Front Immunol       Date:  2013-07-11       Impact factor: 7.561
  10 in total
  9 in total

Review 1.  Current advances of tubulin inhibitors as dual acting small molecules for cancer therapy.

Authors:  Kinsie E Arnst; Souvik Banerjee; Hao Chen; Shanshan Deng; Dong-Jin Hwang; Wei Li; Duane D Miller
Journal:  Med Res Rev       Date:  2019-02-11       Impact factor: 12.944

Review 2.  The Achilles' heel of cancer: targeting tumors via lysosome-induced immunogenic cell death.

Authors:  Taritsa Iulianna; Neote Kuldeep; Fossel Eric
Journal:  Cell Death Dis       Date:  2022-05-30       Impact factor: 9.685

Review 3.  Modulation of APC Function and Anti-Tumor Immunity by Anti-Cancer Drugs.

Authors:  Kea Martin; Jens Schreiner; Alfred Zippelius
Journal:  Front Immunol       Date:  2015-09-29       Impact factor: 7.561

4.  Increased Infiltration of CD8(+) T Cells by Dacarbazine in a Patient with Mucosal Penile Melanoma Refractory to Nivolumab.

Authors:  Masato Funazumi; Takeshi Namiki; Yumi Arima; Kohei Kato; Kohei Nojima; Kentaro Tanaka; Keiko Miura; Hiroo Yokozeki
Journal:  Ann Dermatol       Date:  2016-07-26       Impact factor: 1.444

5.  Autophagy-dependent danger signaling and adaptive immunity to poorly immunogenic tumors.

Authors:  Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncotarget       Date:  2017-01-24

6.  GEF-H1 Signaling upon Microtubule Destabilization Is Required for Dendritic Cell Activation and Specific Anti-tumor Responses.

Authors:  Abhishek S Kashyap; Laura Fernandez-Rodriguez; Yun Zhao; Gianni Monaco; Marcel P Trefny; Naohiro Yoshida; Kea Martin; Ashwani Sharma; Natacha Olieric; Pankaj Shah; Michal Stanczak; Nicole Kirchhammer; Sung-Moo Park; Sebastien Wieckowski; Heinz Laubli; Rachid Zagani; Benjamin Kasenda; Michel O Steinmetz; Hans-Christian Reinecker; Alfred Zippelius
Journal:  Cell Rep       Date:  2019-09-24       Impact factor: 9.423

Review 7.  Mechanisms, Diagnosis and Treatment of Bone Metastases.

Authors:  Jozef Ban; Valerie Fock; Dave N T Aryee; Heinrich Kovar
Journal:  Cells       Date:  2021-10-29       Impact factor: 6.600

8.  Increased yield of AP-3 by inactivation of asm25 in Actinosynnema pretiosum ssp. auranticum ATCC 31565.

Authors:  Hong Cheng; Guoqing Xiong; Yi Li; Jiaqi Zhu; Xianghua Xiong; Qingyang Wang; Liancheng Zhang; Haolong Dong; Chen Zhu; Gang Liu; Huipeng Chen
Journal:  PLoS One       Date:  2022-03-22       Impact factor: 3.240

Review 9.  Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives.

Authors:  E Krasniqi; G Barchiesi; L Pizzuti; M Mazzotta; A Venuti; M Maugeri-Saccà; G Sanguineti; G Massimiani; D Sergi; S Carpano; P Marchetti; S Tomao; T Gamucci; R De Maria; F Tomao; C Natoli; N Tinari; G Ciliberto; M Barba; P Vici
Journal:  J Hematol Oncol       Date:  2019-10-29       Impact factor: 17.388
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.